Clinical aspects of beta-blockade.
beta-Blocking drugs have no or only a partial beta-agonistic activity (ISA). Since they all bind to beta receptors, they act as competitive inhibitors of the endogenous catecholamines. In addition to this common effect, the beta-blocking drugs also have other properties that may be clinically important, such as extent of beta 1 selectivity, ISA, and lipophilicity. The importance of these properties in the clinical setting is reviewed.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001812:Blood-Brain Barrier; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D009206:Myocardium / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D013329:Structure-Activity Relationship; D013564:Sympathetic Nervous System / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D011943:Receptors, Adrenergic, beta